Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Abstract Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available. Results We report a case series of patients with chronic noninfectious uveitis with incomple...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-07-01
|
| Series: | Journal of Ophthalmic Inflammation and Infection |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12348-023-00336-3 |
| _version_ | 1797774016203718656 |
|---|---|
| author | Mathilde Leclercq Paul Goupillou Hélène Gomez Marc Muraine Ygal Benhamou Nicolas Girszyn Julie Gueudry |
| author_facet | Mathilde Leclercq Paul Goupillou Hélène Gomez Marc Muraine Ygal Benhamou Nicolas Girszyn Julie Gueudry |
| author_sort | Mathilde Leclercq |
| collection | DOAJ |
| description | Abstract Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available. Results We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months. Conclusion In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route. |
| first_indexed | 2024-03-12T22:14:49Z |
| format | Article |
| id | doaj.art-4c86375494de4aa9a4037d24f411ed87 |
| institution | Directory Open Access Journal |
| issn | 1869-5760 |
| language | English |
| last_indexed | 2024-03-12T22:14:49Z |
| publishDate | 2023-07-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Ophthalmic Inflammation and Infection |
| spelling | doaj.art-4c86375494de4aa9a4037d24f411ed872023-07-23T11:22:27ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602023-07-011311610.1186/s12348-023-00336-3Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitisMathilde Leclercq0Paul Goupillou1Hélène Gomez2Marc Muraine3Ygal Benhamou4Nicolas Girszyn5Julie Gueudry6CHU Rouen, Internal Medicine Department, CHU Charles NicolleOphthalmology Department, CHU RouenCHU Rouen, Internal Medicine Department, CHU Charles NicolleOphthalmology Department, CHU RouenCHU Rouen, Internal Medicine Department, CHU Charles NicolleCHU Rouen, Internal Medicine Department, CHU Charles NicolleOphthalmology Department, CHU RouenAbstract Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available. Results We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months. Conclusion In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route.https://doi.org/10.1186/s12348-023-00336-3UveitisTocilizumabBody weightSubcutaneousDrug monitoring |
| spellingShingle | Mathilde Leclercq Paul Goupillou Hélène Gomez Marc Muraine Ygal Benhamou Nicolas Girszyn Julie Gueudry Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis Journal of Ophthalmic Inflammation and Infection Uveitis Tocilizumab Body weight Subcutaneous Drug monitoring |
| title | Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis |
| title_full | Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis |
| title_fullStr | Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis |
| title_full_unstemmed | Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis |
| title_short | Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis |
| title_sort | efficacious switching from subcutaneous to intravenous tocilizumab in patients with non infectious non anterior uveitis |
| topic | Uveitis Tocilizumab Body weight Subcutaneous Drug monitoring |
| url | https://doi.org/10.1186/s12348-023-00336-3 |
| work_keys_str_mv | AT mathildeleclercq efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT paulgoupillou efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT helenegomez efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT marcmuraine efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT ygalbenhamou efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT nicolasgirszyn efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis AT juliegueudry efficaciousswitchingfromsubcutaneoustointravenoustocilizumabinpatientswithnoninfectiousnonanterioruveitis |